Mani Aruna相关文献与解析，生知库 | 链接生命科学的每一步

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

伊帕他替尼联合紫杉醇治疗PIK3CA/AKT1/PTEN改变的激素受体阳性HER2阴性晚期乳腺癌：IPATunity130随机3期试验B组的主要结果

Turner, Nicholas; Dent, Rebecca A; O'Shaughnessy, Joyce; Kim, Sung-Bae; Isakoff, Steven J; Barrios, Carlos; Saji, Shigehira; Bondarenko, Igor; Nowecki, Zbigniew; Lian, Qinshu; Reilly, Sarah-Jayne; Hinton, Heather; Wongchenko, Matthew J; Kovic, Bruno; Mani, Aruna; Oliveira, Mafalda

肿瘤

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

一项 Ib/II 期单臂试验评估依维莫司、拉帕替尼和卡培他滨联合治疗 HER2 阳性乳腺癌脑转移的疗效（TRIO-US B-09）

期刊:Therapeutic Advances in Medical Oncology

影响因子:4.2

doi:10.1177/1758835918807339

Hurvitz, Sara; Singh, Rashi; Adams, Brad; Taguchi, Julie A; Chan, David; Dichmann, Robert A; Castrellon, Aurelio; Hu, Eddie; Berkowitz, Jonathan; Mani, Aruna; DiCarlo, Brian; Callahan, Rena; Smalberg, Ira; Wang, Xiaoyan; Meglar, Ivana; Martinez, Diego; Hobbs, Evthokia; Slamon, Dennis J

NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

细胞因子可增强叶酸偶联免疫球蛋白的NK细胞介导的抗肿瘤作用

期刊:Cancer Immunology Research

影响因子:8.2

doi:10.1158/2326-6066.CIR-15-0168

Jaime-Ramirez, Alena C; McMichael, Elizabeth; Kondadasula, SriVidya; Skinner, Cassandra C; Mundy-Bosse, Bethany L; Luedke, Eric; Jones, Natalie B; Mani, Aruna; Roda, Julie; Karpa, Volodymyr; Li, Hong; Li, Jilong; Elavazhagan, Saranya; La Perle, Krista M; Schmitt, Alessandra C; Lu, Yanhui; Zhang, Xiaoli; Pan, Xueliang; Mao, Hsaioyin; Davis, Melanie; Jarjoura, David; Butchar, Jonathan P; Poi, Ming; Phelps, Mitch; Tridandapani, Susheela; Byrd, John C; Caligiuri, Michael A; Lee, Robert J; Carson, William E 3rd

Defining the survival benchmark for breast cancer patients with systemic relapse

确定全身复发乳腺癌患者的生存基准

期刊:Breast Cancer-Basic and Clinical Research

影响因子:1.9

doi:10.4137/BCBCR.S23794

Zeichner, Simon B; Ambros, Tadeu; Zaravinos, John; Montero, Alberto J; Mahtani, Reshma L; Ahn, Eugene R; Mani, Aruna; Markward, Nathan J; Vogel, Charles L

IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production

IL-12 通过 NK 细胞产生 IFN-γ 来增强曲妥珠单抗的抗肿瘤作用。

期刊:Journal of Immunology

影响因子:3.4

doi:10.4049/jimmunol.1000328

Jaime-Ramirez, Alena Cristina; Mundy-Bosse, Bethany L; Kondadasula, SriVidya; Jones, Natalie B; Roda, Julie M; Mani, Aruna; Parihar, Robin; Karpa, Volodymyr; Papenfuss, Tracey L; LaPerle, Krista M; Biller, Elizabeth; Lehman, Amy; Chaudhury, Abhik Ray; Jarjoura, David; Burry, Richard W; Carson, William E 3rd

Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.

I 期主动免疫疗法，将两种嵌合的人表皮生长因子受体 2 B 细胞表位与一种广谱 T 细胞表位融合，用于治疗转移性和/或复发性实体瘤患者

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO.2009.22.3883

Kaumaya Pravin T P, Foy Kevin Chu, Garrett Joan, Rawale Sharad V, Vicari Daniele, Thurmond Jennifer M, Lamb Tammy, Mani Aruna, Kane Yahaira, Balint Catherine R, Chalupa Donald, Otterson Gregory A, Shapiro Charles L, Fowler Jeffrey M, Grever Michael R, Bekaii-Saab Tanios S, Carson William E 3rd

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

一项针对既往接受曲妥珠单抗治疗失败的转移性乳腺癌 (MBC) 患者的 II 期试验，评估曲妥珠单抗联合低剂量白细胞介素-2 (IL-2) 的疗效。

期刊:Breast Cancer Research and Treatment

影响因子:3

doi:10.1007/s10549-008-0251-7

Mani, Aruna; Roda, Julie; Young, Donn; Caligiuri, Michael A; Fleming, Gini F; Kaufman, Peter; Brufsky, Adam; Ottman, Susan; Carson, William E 3rd; Shapiro, Charles L

Apoptosis of multiple myeloma

多发性骨髓瘤细胞凋亡

期刊:International Journal of Hematology

影响因子:1.8

doi:10.1532/ijh97.04107

Oancea, Marcela; Mani, Aruna; Hussein, Mohamad A; Almasan, Alexandru

Cognitive functioning and functional ability in women with schizophrenia and homelessness

患有精神分裂症和无家可归的女性的认知功能和功能能力

Characterization of an extreme phenotype of schizophrenia among women with homelessness

对无家可归女性中精神分裂症极端表型的特征描述

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

伊帕他替尼联合紫杉醇治疗PIK3CA/AKT1/PTEN改变的激素受体阳性HER2阴性晚期乳腺癌：IPATunity130随机3期试验B组的主要结果

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

一项 Ib/II 期单臂试验评估依维莫司、拉帕替尼和卡培他滨联合治疗 HER2 阳性乳腺癌脑转移的疗效（TRIO-US B-09）

NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

细胞因子可增强叶酸偶联免疫球蛋白的NK细胞介导的抗肿瘤作用

Defining the survival benchmark for breast cancer patients with systemic relapse

确定全身复发乳腺癌患者的生存基准

IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production

IL-12 通过 NK 细胞产生 IFN-γ 来增强曲妥珠单抗的抗肿瘤作用。

Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.

I 期主动免疫疗法，将两种嵌合的人表皮生长因子受体 2 B 细胞表位与一种广谱 T 细胞表位融合，用于治疗转移性和/或复发性实体瘤患者

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

一项针对既往接受曲妥珠单抗治疗失败的转移性乳腺癌 (MBC) 患者的 II 期试验，评估曲妥珠单抗联合低剂量白细胞介素-2 (IL-2) 的疗效。

Apoptosis of multiple myeloma

多发性骨髓瘤细胞凋亡